

PROJECT TITLE	RESEARCHER	INSTITUTION	AMOUNT
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors	Nai-Kong V. Cheung MD, PhD & Ellen Basu, MD, PhD	Memorial Sloan Kettering Cancer Center	\$1,500,000
GMP Manufacture and Clinical Testing of Hu3F8-IgG1n (Turbo 3F8)	Nai-Kong V. Cheung MD, PhD & Stephen S. Roberts	Memorial Sloan Kettering Cancer Center	\$1,500,000
GMP Manufacture and Clinical Testing of an Hu3F8 Bi-Specific Antibody	Nai-Kong V. Cheung MD, PhD	Memorial Sloan Kettering Cancer Center	\$2,000,000
MIBG Trail	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$40,000
Combination of Cell-Mediated and Antibody-Mediated Immunotherapy for High-Risk Neuroblastoma: Phase I Study of Haploidentical Natural Killer Cells plus Humanized 3F8	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$700,000
Bivalent Vaccine Plus Beta-Glucan for High-Risk Neuroblastoma in First Remission	Brian H. Kushner, MD	Memorial Sloan Kettering Cancer Center	\$300,000
Reduced Dose Radiotherapy Trial	Dr. Wolden	Memorial Sloan Kettering Cancer Center	\$5,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: Neuroblastoma	John Maris, MD & Yael Mosse, MD	Children’s Hospital of Philadelphia (CHOP)	\$400,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: Neuroblastoma	Wing Leung, MD, PhD	St. Jude Children’s Research Hospital	\$45,000
New Approaches to Neuroblastoma Therapy (NANT)	Various	Consortium of Leading Hospitals	\$125,000
The John K. Bartosz Memorial Fellowship in Pediatric Immunotherapy		Memorial Sloan Kettering Cancer Center	\$267,000
Combination immunotherapy with targeted radiotherapy in children with neuroblastoma	Juliet Gray, MD; Paul Sondel MD, PhD; Holger Lode, MD; Mark Gaze, MD	University Hospital London, University Hospital Southampton UK, University of Wisconsin, Madison, University Medicine, Greifswald, Germany	\$125,000
Prevention of ototoxicity in children with Neuroblastoma (Reduce Cis-platin Hearing Loss with Enols)	Dr. Richard M. Lopachin	Montefiore Medical Center	\$175,000
Novel Immunotherapy Combinations with Dinutuximab Phase I & II Trials	Araz Marachelian, MD	Children's Hospital of Los Angeles	\$300,000
Nurse Navigator as part of the Nepenthe Trial	John Maris, MD & Yael Mosse, MD	Children's Hospital of Philadelphia (CHOP)	\$320,000
Phase II Trial of a Bivalent Vaccine with the Immunological Adjuvant OPT-821, in Combination with Oral Beta-Glucan for High Risk Neuroblastoma for Patients in First Remission and Patients After Relapse	Brian Kushner, MD	Memorial Sloan Kettering Cancer Center	\$1,268,524
Phase I Trial of IL15/IL15 Receptor Alpha-Fc Complex for Post-Therapy Lymphopenia in Children	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$617,400
Phase I/II Bivalent Vaccine	Brian Kushner, MD	Memorial Sloan Kettering Cancer Center	\$1,013,874
Transatlantic Integration Targeting ALK in Neuroblastoma	Lucas Moreno, MD	Various	\$200,000
Analysis to Identify Markers of Poor Survival in High Risk Neuroblastoma	Lucas Moreno, MD	Various	\$75,000
Reducing Cisplatin Hearing Loss with Enols Phase II	Daniel Weiser, MD	Montefiore Medical Center	\$266,190
Novel Anti-B7H3 and Anti-GD2 Immunotherapy Phase I	Araz Marachelian, MD and Shahab Asgharzadeh, MD	Children's Hospital of Los Angeles	\$400,000